Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Long-Term Investments: 2018-2025

Historic Long-Term Investments for Ascendis Pharma A (ASND) over the last 6 years, with Sep 2025 value amounting to $33.1 million.

  • Ascendis Pharma A's Long-Term Investments was N/A to $33.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.1 million, marking a year-over-year change of. This contributed to the annual value of $14.7 million for FY2024, which is 140.16% up from last year.
  • Latest data reveals that Ascendis Pharma A reported Long-Term Investments of $33.1 million as of Q3 2025, which was down 16.25% from $39.5 million recorded in Q2 2025.
  • Ascendis Pharma A's 5-year Long-Term Investments high stood at $123.0 million for Q4 2021, and its period low was -$12.3 million during Q1 2021.
  • Moreover, its 3-year median value for Long-Term Investments was $19.5 million (2023), whereas its average is $23.0 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Long-Term Investments slumped by 188.86% in 2021, and later skyrocketed by 419.89% in 2022.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's Long-Term Investments stood at $123.0 million in 2021, then tumbled by 80.99% to $23.4 million in 2022, then plummeted by 73.85% to $6.1 million in 2023, then soared by 137.11% to $14.5 million in 2024, then reached $33.1 million in 2025.
  • Its Long-Term Investments was $33.1 million in Q3 2025, compared to $39.5 million in Q2 2025 and $43.1 million in Q1 2025.